

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 13, 2000

BECTON, DICKINSON AND COMPANY

(Exact name of registrant as specified in its charter)

New Jersey

001-4802

22-0760120

(State or other juris-
diction of incorporation)

(Commission
File Number)

(IRS Employer Iden-
tification Number)

1 Becton Drive, Franklin Lakes, New Jersey

07417-1880

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code

(201) 847-6800

N/A

(Former name or former addresses if changed since last report.)

Item 9. Regulation FD Disclosure

See the supplemental financial information attached hereto as
Exhibit 99, which is incorporated herein by reference.

INDEX TO EXHIBITS

Exhibit
Number

Description of Exhibits

99

Supplemental Financial Information

BD
 FY 2000
 Revenues by Business Segments and Major Product Groups
 (\$ in Millions)

<TABLE>
 <CAPTION>

	Quarter 4		Total Year
% Growth	Amount	% Growth	Amount

<S>	<C>	<C>	<C>
<C>			
Medical			
Injection Systems	\$ 153	-0.7%	\$ 609
5.8%			
Infusion Therapy Systems	79	-5.1%	342
2.1%			
Consumer Health Care	143	-10.7%	505
-1.5%			
Pharmaceutical Systems	66	13.6%	255
7.1%			
Other	61	-5.1%	255
-2.9%			

	502	-3.4%	1,966
2.2%			
Preanalytical Solutions	131	2.2%	535
5.1%			
Biosciences			
Flow Cytometry	113	35.1%	407
36.3%			
Microbiology	137	2.2%	568
2.7%			
Labware	37	0.5%	143
6.2%			

	287	12.7%	1,118
13.4%			

Total Company	\$ 920	1.9%	\$ 3,618
5.8%			
=====			

</TABLE>